Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

The 90-kDa heat shock protein (Hsp90) plays an important role in conformational regulation of cellular proteins and thereby cellular signaling and function. As Hsp90 is considered a key component of immune function and its inhibition has become an important target for cancer therapy, we here evaluated the role of Hsp90 in human dendritic cell (DC) phenotype and function. Hsp90 inhibition significantly decreased cell surface expression of costimulatory (CD40, CD80, CD86), maturation (CD83), and MHC (HLA-A, B, C and HLA-DP, DQ, DR) markers in immature DC and mature DC and was associated with down-regulation of both RNA and intracellular protein expression. Importantly, Hsp90 inhibition significantly inhibited DC function. It decreased Ag uptake, processing, and presentation by immature DC, leading to reduced T cell proliferation in response to tetanus toxoid as a recall Ag. It also decreased the ability of mature DC to present Ag to T cells and secrete IL-12 as well as induce IFN-γ secretion by allogeneic T cells. These data therefore demonstrate that Hsp90-mediated protein folding is required for DC function and, conversely, Hsp90 inhibition disrupts the DC function of significant relevance in the setting of clinical trials evaluating novel Hsp90 inhibitor therapy in cancer.

[1]  M. Sherman,et al.  Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. , 2006, Cancer research.

[2]  T. Libermann,et al.  Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.

[3]  P. Richardson,et al.  Novel biological therapies for the treatment of multiple myeloma. , 2005, Best practice & research. Clinical haematology.

[4]  Peter Bosma,et al.  Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. , 2005, Experimental cell research.

[5]  J. Liao,et al.  Induction of Angiogenesis by Heat Shock Protein 90 Mediated by Protein Kinase Akt and Endothelial Nitric Oxide Synthase , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Jason C. Young,et al.  Pathways of chaperone-mediated protein folding in the cytosol , 2004, Nature Reviews Molecular Cell Biology.

[7]  J. Beliakoff,et al.  Hsp90: an emerging target for breast cancer therapy , 2004, Anti-cancer drugs.

[8]  L. Whitesell,et al.  Altered Hsp90 function in cancer: a unique therapeutic opportunity. , 2004, Molecular cancer therapeutics.

[9]  D. Taub,et al.  Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers , 2004, Cancer biology & therapy.

[10]  P. Csermely,et al.  Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors. , 2004, Immunology letters.

[11]  P. Csermely,et al.  Inhibition of Hsp90: a new strategy for inhibiting protein kinases. , 2004, Biochimica et biophysica acta.

[12]  P. Workman.  Altered states: selectively drugging the Hsp90 cancer chaperone. , 2004, Trends in molecular medicine.

[13]  L. Neckers,et al.  17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. , 2004, Blood.

[14]  L. Cebotaru,et al.  Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. , 2004, Physiological genomics.

[15]  H. Scher,et al.  Hsp90 as a therapeutic target in prostate cancer. , 2003, Seminars in oncology.

[16]  John H Kersey,et al.  FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  P. Workman,et al.  The clinical applications of heat shock protein inhibitors in cancer - present and future. , 2003, Current cancer drug targets.

[18]  E. Sausville,et al.  Clinical development of 17-allylamino, 17-demethoxygeldanamycin. , 2003, Current cancer drug targets.

[19]  W. Hiddemann,et al.  Molecular characterization of acute leukemias by use of microarray technology , 2003, Genes, chromosomes & cancer.

[20]  M. Goetz,et al.  The Hsp90 chaperone complex as a novel target for cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Keiji Tanaka,et al.  The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome , 2003, The EMBO journal.

[22]  L. Neckers.  Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. , 2003, Current medicinal chemistry.

[23]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[24]  W. Pratt,et al.  Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.

[25]  N. Rosen,et al.  Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. , 2002, Bioorganic & medicinal chemistry.

[26]  D. Picard,et al.  Heat-shock protein 90, a chaperone for folding and regulation , 2002, Cellular and Molecular Life Sciences CMLS.

[27]  Keiji Tanaka,et al.  Two Distinct Pathways Mediated by PA28 and hsp90 in Major Histocompatibility Complex Class I Antigen Processing , 2002, The Journal of experimental medicine.

[28]  N. Munshi,et al.  Adeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation. , 2002, Cancer research.

[29]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  T. Luft,et al.  IFN‐α enhances CD40 ligand‐mediated activation of immature monocyte‐derived dendritic cells , 2002 .

[31]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[32]  W. Cho,et al.  Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  B. Falini,et al.  Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. , 2002, Cancer research.

[34]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.

[35]  P. Srivastava,et al.  Roles of heat-shock proteins in antigen presentation and cross-presentation. , 2002, Current opinion in immunology.

[36]  A. Goldberg,et al.  Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. , 2001, Molecular cell.

[37]  P. Srivastava,et al.  An Endoplasmic Reticulum Protein Implicated in Chaperoning Peptides to Major Histocompatibility of Class I Is an Aminopeptidase* , 2001, The Journal of Biological Chemistry.

[38]  G. Bahr,et al.  Enhanced maturation and functional capacity of monocyte‐derived immature dendritic cells by the synthetic immunomodulator Murabutide , 2001, Immunology.

[39]  R. Binder,et al.  Heat Shock Protein-chaperoned Peptides but Not Free Peptides Introduced into the Cytosol Are Presented Efficiently by Major Histocompatibility Complex I Molecules* , 2001, The Journal of Biological Chemistry.

[40]  Y. Yarden,et al.  Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.

[41]  D. Chen,et al.  Heat shock protein 70 moderately enhances peptide binding and transport by the transporter associated with antigen processing. , 2001, Immunology letters.

[42]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[43]  H. Kawasaki,et al.  A Critical Role for the Proteasome Activator PA28 in the Hsp90-dependent Protein Refolding* , 2000, The Journal of Biological Chemistry.

[44]  L. Whitesell,et al.  Effects of Geldanamycin, a Heat-Shock Protein 90-Binding Agent, on T Cell Function and T Cell Nonreceptor Protein Tyrosine Kinases1 , 2000, The Journal of Immunology.

[45]  P. Csermely,et al.  The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation , 2000, Cell stress & chaperones.

[46]  D. Toft,et al.  The Importance of ATP Binding and Hydrolysis by Hsp90 in Formation and Function of Protein Heterocomplexes* , 1999, The Journal of Biological Chemistry.

[47]  D. Toft,et al.  The Assembly of Progesterone Receptor-hsp90 Complexes Using Purified Proteins* , 1998, The Journal of Biological Chemistry.

[48]  F. Hartl,et al.  In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis , 1998, The Journal of cell biology.

[49]  L. Pearl,et al.  ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo , 1998, The EMBO journal.

[50]  P. Csermely,et al.  The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes. , 1998, Life sciences.

[51]  S. Kostense,et al.  Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice. , 1998, Antiviral research.

[52]  Bernd Bukau,et al.  The Hsp70 and Hsp60 Chaperone Machines , 1998, Cell.

[53]  K. Irie,et al.  Radicicol Leads to Selective Depletion of Raf Kinase and Disrupts K-Ras-activated Aberrant Signaling Pathway* , 1998, The Journal of Biological Chemistry.

[54]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[55]  L. Pearl,et al.  Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.

[56]  M. Clerici,et al.  Type 1 and type 2 cytokines in HIV infection -- a possible role in apoptosis and disease progression. , 1997, Annals of medicine.

[57]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[58]  J. Berzofsky,et al.  Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. , 1997, Journal of immunology.

[59]  L. Neckers,et al.  Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin* , 1996, The Journal of Biological Chemistry.

[60]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[61]  L. Whitesell,et al.  Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. , 1996, Molecular endocrinology.

[62]  Mikhail V. Blagosklonny,et al.  Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association (*) , 1995, The Journal of Biological Chemistry.

[63]  L. Neckers,et al.  Geldanamycin selectively destabilizes and conformationally alters mutated p53. , 1995, Oncogene.

[64]  P. Russell,et al.  A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. , 1994, The EMBO journal.

[65]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Miller,et al.  Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. , 1994, Cancer research.

[67]  D. Toft,et al.  Reconstitution of progesterone receptor with heat shock proteins. , 1990, Molecular endocrinology.